Disclaimer: Due to limited expertise, errors are inevitable, and some information may not be the most up-to-date. Comments pointing out any inaccuracies are welcome. This article is only an introduction to drugs related to healthcare and is not a recommendation of treatment plans (if involved). This article does not constitute any investment advice.
Recently, Gilead Sciences released its Q2 2024 earnings.: Total revenue in the first half of 2024 was $13.64 billion, a year-on-year increase of 5%;Total revenue for Q2 2024 was $6.954 billion, representing a 5% increase compared to the same period last year.This is mainly due to the growth in sales of HIV, oncology, and liver disease drugs.R&D investment was $1.351 billion, a year-on-year decrease of 4%.As of June 30, 2024, Gilead Sciences, Inc.'s cash, cash equivalents, and marketable debt securities were $2.8 billion, compared to $8.4 billion as of December 31, 2023. The decrease was primarily due to the $3.9 billion acquisition of CymaBay Therapeutics and the repayment of $1.75 billion in senior notes.
In the field of anti-infectives business, the company's core pillar incomeRevenue from anti-HIV infection (HIV) drugs was $4.7 billion, a year-on-year increase of 3%., mainly due to the increased demand in the fields of treatment and preventionIn 2024 Q2, Biktarvy® sales reached $3.2 billion, representing an 8% year-over-year increase.Descovy® Sales were $485 million, a year-on-year decrease of 6%.Hepatology Business Revenue Reaches $8.32 Billion, a 17% Increase Year-over-YearThis is mainly due to the increase in average realized prices driven by the U.S. channel mix, as well as increased demand for chronic hepatitis C virus (HCV), chronic hepatitis B virus (HBV), and European chronic hepatitis D virus (HDV) products. In Q2 2024, Veklury's sales were $214 million, a year-over-year decrease of 16%, primarily due to the reduction in COVID-19-related hospitalization rates.
In terms of cell therapy, two CAR-T Products Yescarta® and Tecartus® Achieve Total Sales of $1.001 Billion (Approx. 7.2 Billion Yuan) in H1 2024; Q2 2024 Sales Reach $521 Million (Approx. 3.7 Billion Yuan), Representing an 11% Increase Compared to the Same Period in 2023.Yescarta is the world's first chimeric antigen receptor T-cell (CAR-T) therapy product for adult patients with relapsed or refractory large B-cell lymphoma (R/R LBCL) who have received two or more lines of systemic therapy.2024 H1 YescartaRevenue of $7.94 billion, a year-on-year increase of 7%;2024 Q2 Revenue of $414 Million, a Year-over-Year Increase of 9%The main reason is the increased demand for relapsed or refractory large B-cell lymphoma outside the United States.Tecartus is a CD19-targeted autologous CAR-T cell therapy, the third CAR-T therapy to be approved globally. It is the first CAR-T cell therapy approved for the treatment of adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL), and also the world’s first CAR-T cell therapy for mantle cell lymphoma (MCL).2024 H1 TecartusRevenue of $207 million, a year-on-year increase of 17%;024 Q2 revenue was US$107 million, a year-over-year increase of 21%.Mainly due to relapsed or refractory (R/R) The demand for adult acute lymphoblastic leukemia and relapsed or refractory mantle cell lymphoma is increasing.
In the future, Gilead will continue to strengthen its leadership position in the field of cell therapy.
Reference: Company Announcement
